Table 4. Genes significantly changed by acute nicotine treatment as confirmed by real-time PCR.
Gene symbol | Gene | Ratio ± SDa | p value | FDRb |
---|---|---|---|---|
DUSP | Dual specificity phosphatase 2 | 1.23 ± 0.04 | 0.005 | 0.025 |
IL6ST | Interleukin 6 signal transducer | 0.81 ± 0.04 | 0.013 | 0.028 |
TRAF6 | Tnf receptor-associated factor 6 | 0.90 ± 0.01 | 0.027 | 0.035 |
TGFBR2 | Transforming growth factor, beta receptor 2 | 0.73 ± 0.07 | 0.009 | 0.028 |
ITGB1 | Integrin beta 1 | 0.73 ± 0.10 | 0.004 | 0.025 |
HMGN1 | High mobility group nucleosomal binding domain 1 | 1.37 ± 0.07 | 0.028 | 0.035 |
DAXX | Fas death domain-associated protein | 1.12 ± 0.06 | 0.023 | 0.035 |
MAPK14 | Mitogen-activated protein kinase 14 | 1.14 ± 0.05 | 0.014 | 0.028 |
The ratio shown in this column is between gene expression in the nicotine-treated and control groups. For the ten genes verified by real-time PCR, the expression of eight is significantly (p < 0.05) different in response to acute nicotine treatment. For the other two genes, i.e., ARAF1 and RPS6KB1, the p value is 0.197 and 0.519, respectively. Although the expression change of the two genes did not reach significance, they showed a trend in the same direction as that detected with the microarray approach
FDR is calculated from the p values of the ten genes verified by real-time PCR via the method of Benjamini and Hochberg (1995). For ARAF1 and RPS6KB1, the FDR is 0.219 and 0.519, respectively; the values are not shown in the table, because the expression difference in the two genes was not significant in real-time PCR tests